^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    High ALC

    Apply
    Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT02890329)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/05/2017
    Primary completion :
    10/24/2022
    Completion :
    08/19/2025
    CD4
    |
    High ALC
    |
    Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)